Small and effective: The pathological aggregation of amylin (IAPP), which leads to type II diabetes mellitus, is effectively inhibited by small-molecule rhodanine-based inhibitors at nanomolar concentrations. The prevention of aggregation by treatment with the inhibitor is demonstrated by AFM (see image).
No takes yet. Share an insight, caveat, or question.
Mishra et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: